Volume 59, Issue 1, Pages (January 2011)

Slides:



Advertisements
Similar presentations
Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study  Wesley.
Advertisements

The PSA Era is not Over for Prostate Cancer
Volume 59, Issue 2, Pages (February 2011)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 70, Issue 1, Pages (July 2016)
Volume 63, Issue 5, Pages (May 2013)
Volume 61, Issue 1, Pages (January 2012)
Volume 73, Issue 1, Pages (January 2018)
Volume 51, Issue 2, Pages (February 2007)
The Correlation Between Metabolic Syndrome and Prostatic Diseases
Volume 53, Issue 5, Pages (May 2008)
Volume 64, Issue 4, Pages (October 2013)
Volume 51, Issue 4, Pages (April 2007)
Volume 59, Issue 1, Pages (January 2011)
Volume 53, Issue 5, Pages (May 2008)
Volume 66, Issue 6, Pages (December 2014)
Volume 71, Issue 6, Pages e171-e172 (June 2017)
Let the Games Begin (with EAU Approval)
Prostate Cancer Epidemic in Sight?
Volume 63, Issue 1, Pages (January 2013)
The Global Risk of Bladder Cancer: Let's Just Do Something About It!
Volume 59, Issue 6, Pages (June 2011)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey  John B. McKinlay, Carol L. Link  European.
Volume 51, Issue 1, Pages (January 2007)
Towards Early and More Specific Diagnosis of Prostate Cancer
Prostate Cancer Detection: A View of the Future
Re: David J. McConkey, Woonyoung Choi, Colin P. N. Dinney
CEACAM1: A Novel Urinary Marker for Bladder Cancer Detection
P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes  European Urology 
Volume 63, Issue 5, Pages (May 2013)
Volume 64, Issue 4, Pages (October 2013)
Obesity and Prostate Cancer: A Role for Adipokines
Volume 69, Issue 3, Pages (March 2016)
Volume 70, Issue 1, Pages (July 2016)
Volume 64, Issue 3, Pages (September 2013)
Volume 57, Issue 4, Pages e41-e42 (April 2010)
Volume 61, Issue 5, Pages (May 2012)
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
Molecular Tumour Profiling for Detection of Biomarkers in Renal Cell Tumours  Kerstin Junker, Jimsgene Sanjmyatav, Joerg Mueller, Thomas Steiner, Heiko.
Volume 70, Issue 1, Pages e27-e28 (July 2016)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 66, Issue 6, Pages (December 2014)
Volume 63, Issue 3, Pages (March 2013)
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Volume 71, Issue 1, Pages (January 2017)
The Inside-Out Transobturator Male Sling for the Surgical Treatment of Stress Urinary Incontinence After Radical Prostatectomy: Midterm Results of a Single-Center.
The Lethal Clone in Prostate Cancer: Redefining the Index
Volume 61, Issue 6, Pages (June 2012)
Volume 61, Issue 5, Pages (May 2012)
The Economic Costs of Overactive Bladder in Germany
Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl  European Urology 
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 51, Issue 1, Pages (January 2007)
Testicular Cancer Variations in Time and Space in Europe
Volume 53, Issue 1, Pages (January 2008)
Prognostic Impact of Comorbidity in Patients with Bladder Cancer
Y. -P. Ding, M. -F. Liang, J. -b. Ye, Q. -h. Liu, C. -h. Xiong, B
European Urology is “Your” Journal
Volume 51, Issue 5, Pages (May 2007)
Economic Burden of Bladder Cancer Across the European Union
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson 
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Neal S Goldstein, MD  The Annals of Thoracic Surgery 
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 59, Issue 1, Pages 113-119 (January 2011) Stress Proteins and Cytokines are Urinary Biomarkers for Diagnosis and Staging of Bladder Cancer  David Margel, Meirav Pesvner-Fischer, Jack Baniel, Ofer Yossepowitch, Irun R. Cohen  European Urology  Volume 59, Issue 1, Pages 113-119 (January 2011) DOI: 10.1016/j.eururo.2010.10.008 Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 1 Urinary concentrations of heat shock protein (HSP) HSP60, HSP70, and HSP90. Urine was assayed by enzyme-linked immunosorbent assay for the presence of (a) HSP60, (b) HSP70, and (c) HSP90. The results are presented by a scatter plot, with each dot representing one patient. One dot is presented when urinary concentrations overlap and the number of overlapping patients is indicated. The mean of each group is presented by a line. BC=bladder cancer; MI=muscle-invasive; non-MI=non–muscle-invasive. European Urology 2011 59, 113-119DOI: (10.1016/j.eururo.2010.10.008) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 2 Urinary concentrations of cytokines. Urine was assayed by enzyme-linked immunosorbent assay for the presence of (a) interleukin (IL)-13, (b) IL-10 (c) IL-8, (d) IL-6, and (e) tumor growth factor (TGF)-β. The results are presented by a scatter plot. Each dot represents one patient. One dot is presented when urinary concentrations overlap and the number of overlapping patients is indicated. BC=bladder cancer; MI=muscle-invasive; non-MI=non–muscle-invasive. European Urology 2011 59, 113-119DOI: (10.1016/j.eururo.2010.10.008) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 3 Receiver operating curve of (a) heat shock protein (HSP) molecules (a) and (b) cytokines in bladder cancer detection. IL=interleukin; TGF=tumor growth factor. European Urology 2011 59, 113-119DOI: (10.1016/j.eururo.2010.10.008) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 4 Receiver operating curve of (a) heat shock protein (HSP) molecules and (b) cytokines for bladder cancer stage prediction. IL=interleukin; TGF=tumor growth factor. European Urology 2011 59, 113-119DOI: (10.1016/j.eururo.2010.10.008) Copyright © 2010 European Association of Urology Terms and Conditions